Our findings set the cellular and molecular basis for the inhibitory function of KIR2DL5 and demonstrate the therapeutic potential of blocking the KIR2DL5/PVR pathway in NK cell–based cancer immunotherapy. This evidence concerns the gene PVR and cancer.